ANI Pharmaceuticals (NASDAQ:ANIP) Hits New 1-Year Low – Here’s What Happened

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares reached a new 52-week low during mid-day trading on Thursday. The stock traded as low as $69.39 and last traded at $69.6420, with a volume of 919,002 shares changing hands. The stock had previously closed at $71.65.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI reported third-quarter 2026 adjusted earnings of $2.70 per share, above estimates of about $2.18 and up from $2.04 a year earlier. Revenue rose 27.6% year over year to $290.78 million, also topping analyst expectations. ANI Pharmaceuticals third-quarter 2026 results
• Positive Sentiment: ANI proposed acquiring Swedish biotech Egetis Therapeutics for about $560 million. The deal would expand ANI’s rare-disease business and could provide a longer-term growth opportunity if completed and successfully integrated. ANI offer to acquire Egetis Therapeutics
• Negative Sentiment: The acquisition proposal also brings financing, deal-completion and integration risks. Investors may be assessing whether the $560 million purchase price will generate sufficient returns, tempering the positive read-through from the earnings beat.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Canaccord Genuity Group reduced their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Guggenheim cut their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 target price for the company. Finally, Oppenheimer began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 price target on the stock. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $99.60.

ANI Pharmaceuticals Trading Down 2.8%

The firm has a market capitalization of $1.60 billion, a P/E ratio of 15.01, a PEG ratio of 2.33 and a beta of 0.45. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The firm has a 50 day moving average of $72.74 and a 200-day moving average of $77.49.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.18 by $0.52. The company had revenue of $290.78 million during the quarter, compared to analysts’ expectations of $280.26 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business’s revenue for the quarter was up 27.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.04 EPS. On average, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen Carey sold 2,850 shares of the business’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $72.87, for a total transaction of $207,679.50. Following the sale, the chief financial officer owned 166,143 shares of the company’s stock, valued at approximately $12,106,840.41. The trade was a 1.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $71.89, for a total value of $388,206.00. Following the completion of the transaction, the chief executive officer owned 333,689 shares of the company’s stock, valued at $23,988,902.21. This represents a 1.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 30,412 shares of company stock worth $2,220,970. Corporate insiders own 8.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Illinois Municipal Retirement Fund grew its holdings in ANI Pharmaceuticals by 7.2% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 9,719 shares of the specialty pharmaceutical company’s stock valued at $706,000 after buying an additional 651 shares in the last quarter. Penn Capital Management Company LLC boosted its holdings in shares of ANI Pharmaceuticals by 2.8% in the 3rd quarter. Penn Capital Management Company LLC now owns 213,246 shares of the specialty pharmaceutical company’s stock worth $15,515,000 after purchasing an additional 5,884 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of ANI Pharmaceuticals by 4.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 12,695 shares of the specialty pharmaceutical company’s stock valued at $926,000 after purchasing an additional 518 shares in the last quarter. Hohimer Wealth Management LLC grew its position in ANI Pharmaceuticals by 4.1% during the 3rd quarter. Hohimer Wealth Management LLC now owns 3,638 shares of the specialty pharmaceutical company’s stock worth $264,000 after acquiring an additional 142 shares during the last quarter. Finally, Alps Advisors Inc. grew its holdings in shares of ANI Pharmaceuticals by 15.7% in the third quarter. Alps Advisors Inc. now owns 8,242 shares of the specialty pharmaceutical company’s stock worth $599,000 after purchasing an additional 1,117 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.